Taiho Gets Option for Arcus’ Immuno-Oncology Portfolio in Japan, Asia

September 21, 2017
Taiho Pharmaceutical is getting its hands on Arcus Biosciences’ immuno-oncology portfolio, striking an option and licensing pact for the potential development and commercialization of the US biotech’s product candidates in Japan and Asia, excluding China. Arcus was founded in 2015...read more